Minoxidil‐induced hypertrichosis in a breastfed infant

Trüeb, Ralph M.; Caballero-Uribe, N

doi:10.1111/jdv.17755

Cited by 4 publications

(4 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…38 A report of hypertrichosis developing in a 2month-old, preterm, breastfed infant whose mother was applying topical minoxidil 5% twice a day has been associated with the use of the medication, but the association remained inconclusive. 39 Importantly, no information on the safety of oral minoxidil during lactation is available to date.…”

Section: Hairmentioning

confidence: 99%

“…Topical formulations to treat alopecia or hair loss should pose low risk to older, full-term breastfed infants but might best be avoided while breastfeeding a preterm or neonatal infant 38 . A report of hypertrichosis developing in a 2-month-old, preterm, breastfed infant whose mother was applying topical minoxidil 5% twice a day has been associated with the use of the medication, but the association remained inconclusive 39 . Importantly, no information on the safety of oral minoxidil during lactation is available to date.…”

Section: Surgery Cosmetics Hair and Acnementioning

confidence: 99%

See 1 more Smart Citation

Dermatologic drug safety in lactation

Yaghi,

Truong,

Murase

2024

Journal of Dermatology for Physician Assistants

View full text Add to dashboard Cite

In 2014, the US FDA removed the Pregnancy Category Drug lettering system and enacted the “Pregnancy and Lactation Label Ruling.” This ruling required drug products to contain contact information for drug-specific exposure pregnancy registries, narrative-style sections summarizing the known effect of pregnancy, lactation counseling data, and data describing risks for females and males of reproductive potential. This new ruling has added more dialogue and discussion to the patient-provider decision-making process and requires clinicians to provide more individualized counseling based on the current medical literature. This article summarizes the recent evidence for the safety of the most common dermatological therapies for pregnant and lactating women.

show abstract

Section: Hairmentioning

confidence: 99%

Section: Surgery Cosmetics Hair and Acnementioning

confidence: 99%

Dermatologic drug safety in lactation

Yaghi,

Truong,

Murase

2024

Journal of Dermatology for Physician Assistants

View full text Add to dashboard Cite

show abstract

“…7,8 Although topical minoxidil usage by mothers offers no harm to breastfed children according to expert consensus, minoxidil-induced hypertrichosis in a breastfed infant was recently reported. 9 Therefore, minoxidil should be prescribed under supervision, especially when a substantial maternal dosage is part of the therapy and while nursing a premature baby. 9 Elevated estrogen levels during pregnancy slow down the hair follicles' normal cycle of shedding.…”

Section: Introductionmentioning

confidence: 99%

“…9 Therefore, minoxidil should be prescribed under supervision, especially when a substantial maternal dosage is part of the therapy and while nursing a premature baby. 9 Elevated estrogen levels during pregnancy slow down the hair follicles' normal cycle of shedding. As a result, most pregnant women with FPHL can actually have less hair loss.…”

Section: Introductionmentioning

confidence: 99%

Efficacy and Safety of Topical 5% Azelaic Acid Solution Versus 2% Minoxidil Solution in the Treatment of Female Pattern Hair Loss

Thanomkitti,

Pruksaeakanan,

Subchookul

et al. 2023

Siriraj Med J

View full text Add to dashboard Cite

Objective: To determine the efficacy and safety of 5% azelaic acid solution in comparison with 2% minoxidil solution in the treatment of FPHL. Materials and Methods: Twenty-six FPHL patients with Ludwig grade I or II were randomly treated with 5% azelaic acid solution or 2% minoxidil solution twice daily for 6 months. At baseline, 2, 4, and 6 months, hair density and hair shaft diameter were assessed at the targeted fixed area. At 6 months, patient and investigator assessments of hair growth were performed using a 7-point scale. Results: Hair density and hair shaft diameter in the patients treated with 5% azelaic acid and 2% minoxidil solution were significantly increased compared to the baseline in all cases and visits (P < 0.05). There were no statistically significant differences in hair density and hair shaft diameter changes between both groups (P > 0.05). Both the investigator and patient assessments were comparable between both groups at 6 months. Pruritus was the major adverse effect reported in both groups, but only mild and all could be tolerated. Conclusion: 5% Azelaic acid solution might be an effective treatment for FPHL, comparable with 2% minoxidil, and could be an alternative treatment for FPHL in minoxidil-allergic patients and pregnant women.

show abstract